Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Wisconsin, Madison | OTHER |
Not provided
Not provided
Not provided
Not provided
This pilot study purpose of this study is to describe peripheral circulating immune cell profiles at baseline and change on treatment with immune checkpoint inhibitors in renal cell carcinoma and urothelial carcinoma.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group A: Renal Cell Carcinoma | Subjects in Group A (patients with locally advanced, high grade or metastatic renal cell carcinoma starting immunotherapy) will have blood collected at baseline, at the time of a standard of care cytoreductive surgery (if applicable), 12 weeks, 24 weeks, 52 weeks and upon disease progression on treatment for analysis of peripheral blood mononuclear cells (PBMCs), circulating tumor cells (CTCs), metabolites, cytokines and angiokines. Urinary and fecal specimens will be collected at baseline, at the time of a standard of care cytoreductive surgery (if applicable), 12 weeks, 24 weeks, 52 weeks and upon disease progression. Tissue will be collected at the time of a standard of care cytoreductive surgery (if applicable). |
| |
| Group B: Urothelial Carcinoma | Subjects in Group B (patients with locally advanced, high grade or metastatic urothelial carcinoma starting immunotherapy) will have blood collected at baseline, at the time of a standard of care cytoreductive surgery (if applicable), 12 weeks, 24 weeks, 52 weeks and upon disease progression on treatment for analysis of peripheral blood mononuclear cells (PBMCs), circulating tumor cells (CTCs), metabolites, cytokines and angiokines. Urinary and fecal specimens will be collected at baseline, at the time of a standard of care cytoreductive surgery (if applicable), 12 weeks, 24 weeks, 52 weeks and upon disease progression. Tissue will be collected at the time of a standard of care cytoreductive surgery (if applicable). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Immune cell and CTC detection procedures | Device | Immune cell profiling assays (in blood and archival tumor samples) and circulating tumor cell assays (in blood samples) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in the number of T-cells before and after treatment with immune therapies | Baseline and Disease progression (up to two years) | |
| Change in the number of B-cells before and after treatment with immune therapies | Baseline and Disease progression (up to two years) | |
| Change in the number of myeloid-derived suppressor cells (MDSCs) before and after treatment with immune therapies | Baseline and Disease progression (up to two years) | |
| Change in the number of neutrophil cells before and after treatment with immune therapies | Baseline and Disease progression (up to two years) | |
| Number of patients with detectable circulating tumor cells (CTCs) | Disease progression (up to two years) |
| Measure | Description | Time Frame |
|---|---|---|
| The prevalence of tumor-infiltrating lymphocytes for all subjects at baseline | Baseline | |
| The prevalence of tumor-associated macrophages for all subjects at baseline | Baseline | |
Not provided
Inclusion Criteria:
Group A Renal Cell Carcinoma:
Patients will be eligible for inclusion in this study if ALL of the following criteria apply:
Histologically confirmed or radiological diagnosis of renal cell carcinoma. Clear cell and non-clear cell carcinoma (such as papillary, chromophobe, collecting duct, and medullary) allowed.
Evidence of locally advanced, high grade or metastatic disease in any site on most recent imaging scan
Planned initiation of treatment with any of the following:
Age > 18 years.
Ability to understand and the willingness to sign a written informed consent document.
Group B Urothelial Carcinoma:
Patients will be eligible for inclusion in this study if ALL of the following criteria apply:
Histologically confirmed diagnosis of urothelial carcinoma. Non-transitional cell carcinoma (such as adenocarcinoma and squamous cell carcinoma) allowed.
Evidence of locally advanced, high grade or metastatic disease in any site on most recent imaging scan
Planned initiation of treatment with any of the following:
Age > 18 years.
Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
A patient will not be eligible for inclusion in this study if any of the following criteria apply:
1. History of intercurrent or past condition that would make participation in this protocol difficult or not feasible at the discretion of the principal investigator or co-investigator(s).
Not provided
Not provided
Not provided
Duke Cancer Institute Patients
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Daniel George, MD | Duke University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Duke University Medical Center | Durham | North Carolina | 27710 | United States |
Not provided
Not provided
Not provided
Not provided
| The change in CTCs over time |
| Baseline, week 4, week 8, week 12 and progression (up to two years) |
| The distribution of CTCs difference scores across the ordered tumor response categories of CR, PR, SD, and PD | Disease progression (up to two years) |
| The change in tumor burden over time measured by RECIST | Baseline, Week 12, Progression (up to two years) |
| ID | Term |
|---|---|
| D002292 | Carcinoma, Renal Cell |
| D002277 | Carcinoma |
| ID | Term |
|---|---|
| D000230 | Adenocarcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D007680 | Kidney Neoplasms |
| D014571 | Urologic Neoplasms |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052801 | Male Urogenital Diseases |
Not provided
Not provided